AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) have announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY (epcoritamab), a groundbreaking therapy for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) following two or more prior treatments. This approval marks a significant milestone as TEPKINLY becomes the first and only […]
Nordic Nanovector, a Norwegian biopharmaceutical company, has commenced the first clinical site in the United States for its PARADIGME trial. This pivotal trial is designed to assess the efficacy of Betalutin (lilotomab), an innovative anti-CD37 antibody, in treating third-line (3L) follicular lymphoma patients who have previously failed anti-CD20 therapies. PARADIGME Trial Marks a Significant Milestone […]
Kite Pharma has clinched the US FDA approval for its Car T therapy Yescarta (axicabtagene ciloleucel) for treating a type of lymphatic cancer in patients who have no more treatment options left and are staring at a dire prognosis.
In a significant development for lymphoma treatment, Kite Pharma, a subsidiary of Gilead Sciences, has received approval from the U.S. Food and Drug Administration (FDA) for its chimeric antigen receptor T cell (CAR T) therapy, Yescarta (axicabtagene ciloleucel). This new therapy is now approved for adult patients in the United States with relapsed or refractory […]